PDCD1 and lung cancer: No significant difference in PD-1 and CTLA-4 mRNA expression and in lymphocyte counts were observed between 7 lung cancer patients and 18 other malignancies in the immunomodulation therapy cohort, suggesting dysregulated cellular immunity in cancer patients.